<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">CAT</journal-id>
<journal-id journal-id-type="hwp">spcat</journal-id>
<journal-id journal-id-type="nlm-ta">Clin Appl Thromb Hemost</journal-id>
<journal-title>Clinical and Applied Thrombosis/Hemostasis</journal-title>
<issn pub-type="ppub">1076-0296</issn>
<issn pub-type="epub">1938-2723</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1076029611436196</article-id>
<article-id pub-id-type="publisher-id">10.1177_1076029611436196</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Congenital FVII Deficiency and Pulmonary Embolism</article-title>
<subtitle>A Critical Appraisal of All Reported Cases</subtitle>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Girolami</surname>
<given-names>A.</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-1076029611436196">1</xref>
<xref ref-type="corresp" rid="corresp1-1076029611436196"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>de Marinis</surname>
<given-names>G. Berti</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-1076029611436196">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Vettore</surname>
<given-names>S.</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="aff1-1076029611436196">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Girolami</surname>
<given-names>B.</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff2-1076029611436196">2</xref>
</contrib>
</contrib-group>
<aff id="aff1-1076029611436196"><label>1</label>Department of Medical and Surgical Sciences, University of Padua, Medical School, Padua, Italy</aff>
<aff id="aff2-1076029611436196"><label>2</label>Division of Medicine, Padua City Hospital, Padua, Italy</aff>
<author-notes>
<corresp id="corresp1-1076029611436196">A. Girolami, Department of Medical and Surgical Sciences, University of Padua, Via Ospedale 105, 35128 Padua, Italy. Email: <email>antonio.girolami@unipd.it</email>
</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>1</month>
<year>2013</year>
</pub-date>
<volume>19</volume>
<issue>1</issue>
<fpage>55</fpage>
<lpage>59</lpage>
<permissions>
<copyright-statement>© The Author(s) 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>Fourteen patients with congenital factor VII (FVII) deficiency were reported to have had pulmonary embolism. All patients were type 2 defects with variably low activity but normal or near-normal antigen. Concomitant deep vein thrombosis was present in 7 instances. The majority of patients had no or only a mild bleeding tendency. Associated prothrombotic risk factors were present in 11 patients (old age, surgery, substitution therapy with prothrombin complex, plasma-derived or activated FVII concentrates). Pulmonary embolism was usually moderate or severe. In 2 cases, it was fatal. Only 4 patients were studied by means of molecular biology techniques. The Arg304Gln mutation was found in 5 of the 8 alleles. Heparin and Coumadin together with adequate substitution therapy were carried out in 5 patients with satisfactory results. The FVII deficiency does not grant a sure protection from venous thromboembolism.</p>
</abstract>
<kwd-group>
<kwd>FVII deficiency</kwd>
<kwd>pulmonary embolism</kwd>
<kwd>replacement therapy</kwd>
</kwd-group>
<custom-meta-wrap>
<custom-meta>
<meta-name>cover-date</meta-name>
<meta-value>January/February 2013</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<sec id="section1-1076029611436196">
<title>Introduction</title>
<p>Thrombotic events are rare in congenital bleeding disorders. Due to their high prevalence, patients with hemophilia A or B and von Willebrand disease are usually involved.<sup><xref ref-type="bibr" rid="bibr1-1076029611436196">1</xref><xref ref-type="bibr" rid="bibr2-1076029611436196"/>–<xref ref-type="bibr" rid="bibr3-1076029611436196">3</xref></sup> Among the rare coagulation disorders, factor VII (FVII) deficiency has been reported to be more frequently associated with thrombosis.<sup><xref ref-type="bibr" rid="bibr4-1076029611436196">4</xref>,<xref ref-type="bibr" rid="bibr5-1076029611436196">5</xref></sup> Around 50 patients with FVII deficiency have been reported to be associated with venous (more common) or arterial thrombosis (less common).<sup><xref ref-type="bibr" rid="bibr5-1076029611436196">5</xref>,<xref ref-type="bibr" rid="bibr6-1076029611436196">6</xref></sup>
</p>
<p>A few recent articles have dealt with this peculiar association. The overall conclusion of these studies are consistent with the belief that the thrombotic manifestations are due to associated risk factors and that the clotting defect is unable to neutralize the prothrombotic impact of the associated risk factors (trauma, bed immobilization, substitution therapy, specially with prothrombin complex concentrates [PCCs] for venous thrombosis and dyslipidemia, smoking, diabetes, and hypertension for arterial thrombosis).<sup><xref ref-type="bibr" rid="bibr6-1076029611436196">6</xref></sup>
</p>
<p>The existence of a special form of FVII deficiency prone to thrombosis was suspected but never confirmed. Several mutations have been reported in these patients.<sup><xref ref-type="bibr" rid="bibr4-1076029611436196">4</xref>,<xref ref-type="bibr" rid="bibr7-1076029611436196">7</xref>,<xref ref-type="bibr" rid="bibr8-1076029611436196">8</xref></sup> No article has ever dealt in a systematic pattern with pulmonary embolism (PE) in FVII deficiency. The purpose of the present study is to analyze all reported patients of FVII deficiency who manifested PE with or without concomitant deep venous thrombosis.</p>
</sec>
<sec id="section2-1076029611436196" sec-type="methods">
<title>Patients and Methods</title>
<p>Personal files pertaining to the years 1968 to 2002 and 275 reports on congenital FVII deficiency have been analyzed. Sixty articles for a total of 109 cases had already been studied<sup><xref ref-type="bibr" rid="bibr9-1076029611436196">9</xref></sup> by us in 1972. The remaining articles were analyzed after that date. Original articles were obtained through the help of the Pinali Library of our University and the courtesy of Data Med, Sorengo, Switzerland. Cross-examination of the references of the single articles was carried out in order to eliminate potential omissions. The criteria for inclusion were FVII deficiency of less than 20% of normal, a compatible hereditary pattern, and clinical and objective demonstration of the presence of PE. The objective methods for inclusions had to be pulmonary ventilatory/perfusory scintigraphy, spiral computerized axial tomography, or arteriography. The severity of the PE was graded as massive, severe, moderate, and mild according to the information supplied. Associated prothrombotic risk factors and the severity of bleeding tendency were recorded on the basis of the data presented by the authors of the single articles. The bleeding tendency was graded as severe, moderate, or mild according to the information present in each article. All patients with higher levels of FVII activity were excluded. Molecular biology studies were not an absolute requisite for inclusion. However, the mutations seen in most recent cases were recorded.</p>
</sec>
<sec id="section3-1076029611436196">
<title>Results</title>
<p>At least 14 patients with FVII deficiency and proven PE were found.<sup><xref ref-type="bibr" rid="bibr4-1076029611436196">4</xref>,<xref ref-type="bibr" rid="bibr7-1076029611436196">7</xref>,<xref ref-type="bibr" rid="bibr10-1076029611436196">10</xref><xref ref-type="bibr" rid="bibr11-1076029611436196"/><xref ref-type="bibr" rid="bibr12-1076029611436196"/><xref ref-type="bibr" rid="bibr13-1076029611436196"/><xref ref-type="bibr" rid="bibr14-1076029611436196"/><xref ref-type="bibr" rid="bibr15-1076029611436196"/><xref ref-type="bibr" rid="bibr16-1076029611436196"/><xref ref-type="bibr" rid="bibr17-1076029611436196"/><xref ref-type="bibr" rid="bibr18-1076029611436196"/><xref ref-type="bibr" rid="bibr19-1076029611436196"/>–<xref ref-type="bibr" rid="bibr20-1076029611436196">20</xref></sup> The main features of these patients are gathered in <xref ref-type="table" rid="table1-1076029611436196">Table 1</xref>
. Age varied between 21 and 79 (mean 52.4). Six patients were male and 7 female. In one instance, gender was not specified. Level of FVII activity as assayed by a rabbit brain reagent was carried out in 10 cases, which varied between 1% and 15% of normal (mean 6.4). Activity of FVII using human placenta or a human recombinant preparation was carried out in only 4 patients and varied between 9 and 31 (mean 16.2). Activity of FVII using an ox brain preparation was carried out only in one instance and found to be 100% of normal. In 1 case, level of FVII was unknown, but the patient had congenital FVII deficiency.<sup><xref ref-type="bibr" rid="bibr20-1076029611436196">20</xref></sup>
</p>
<table-wrap id="table1-1076029611436196" position="float">
<label>Table 1.</label>
<caption>
<p>Reported Cases of PE With or Without Concomitant DVT in Patients With FVII Deficiency</p>
</caption>
<graphic alternate-form-of="table1-1076029611436196" xlink:href="10.1177_1076029611436196-table1.tif"/>
<table>
<thead>
<tr>
<th rowspan="2">Authors</th>
<th rowspan="2">Gender, Age</th>
<th align="center" colspan="3">FVII activity</th>
<th align="center" rowspan="2">FVII Antigen</th>
<th rowspan="2">Genotype/Mutation</th>
<th rowspan="2">Form of PE</th>
<th rowspan="2">Concomitant DVT</th>
<th rowspan="2">Associated Risk Factors</th>
<th rowspan="2">Bleed Tendency</th>
<th rowspan="2">Comments</th>
</tr>
<tr>
<th>Rabbit</th>
<th>Human</th>
<th>Ox</th>
</tr>
</thead>
<tbody>
<tr>
<td>Godal et al<sup><xref ref-type="bibr" rid="bibr15-1076029611436196">15</xref></sup>
</td>
<td>M, 29</td>
<td>1</td>
<td>nr</td>
<td>nr</td>
<td>nr</td>
<td>Hom/nr</td>
<td>Severe</td>
<td>No</td>
<td>Surgery (perforated duodenal ulcer); whole blood transfusion</td>
<td>None</td>
<td>Two brothers similarly affected</td>
</tr>
<tr>
<td>Hall et al<sup><xref ref-type="bibr" rid="bibr16-1076029611436196">16</xref></sup>
</td>
<td>M, 41</td>
<td>&lt;3</td>
<td>nr</td>
<td>nr</td>
<td>nr</td>
<td>Hom/nr</td>
<td>Massive (fatal)</td>
<td>Yes</td>
<td>Liver cirrhosis</td>
<td>Moderate</td>
<td>Diagnosis at autopsy</td>
</tr>
<tr>
<td>Heikinheimo et al<sup><xref ref-type="bibr" rid="bibr17-1076029611436196">17</xref></sup>
</td>
<td>F, 33</td>
<td>&lt;5</td>
<td>nr</td>
<td>nr</td>
<td>nr</td>
<td>Hom/nr</td>
<td>Moderate</td>
<td>No</td>
<td>Surgery (spondylodesis); whole blood transfusion</td>
<td>Mild</td>
<td>UH together with blood transfusion</td>
</tr>
<tr>
<td>Gershwin et al<sup><xref ref-type="bibr" rid="bibr14-1076029611436196">14</xref></sup>
</td>
<td>M, 21</td>
<td>5</td>
<td>nr</td>
<td>nr</td>
<td>nr</td>
<td>Hom/nr</td>
<td>Severe</td>
<td>Yes</td>
<td>Surgery (pericardectomy); PCC</td>
<td>Mild</td>
<td>UH was administered together with PCC</td>
</tr>
<tr>
<td>Solanki et al<sup><xref ref-type="bibr" rid="bibr19-1076029611436196">19</xref></sup>
</td>
<td>F, 65</td>
<td>&lt;10</td>
<td>nr</td>
<td>nr</td>
<td>nr</td>
<td>Hom/nr</td>
<td>Severe (fatal)</td>
<td>No</td>
<td>Old M.I.; atherosclerosis; biopsy for inflamed breast mass</td>
<td>None</td>
<td>Confirmed by autopsy</td>
</tr>
<tr>
<td>Shifter et al<sup><xref ref-type="bibr" rid="bibr18-1076029611436196">18</xref></sup>
</td>
<td>F, 35</td>
<td>14</td>
<td>nr</td>
<td>nr</td>
<td>20</td>
<td>Hom/nr</td>
<td>Moderate</td>
<td>Yes</td>
<td>Rebound from interruption of oral anticoagulation</td>
<td>None</td>
<td>Antigen level by neutralization test.</td>
</tr>
<tr>
<td>Sabharwal et al<sup><xref ref-type="bibr" rid="bibr10-1076029611436196">10</xref></sup>
</td>
<td>F, 50</td>
<td>nr</td>
<td>14</td>
<td>nr</td>
<td>120</td>
<td>Hom/Arg304Gln</td>
<td>Moderate</td>
<td>Yes</td>
<td>None</td>
<td>nr</td>
<td>
</td>
</tr>
<tr>
<td>Mariani et al<sup><xref ref-type="bibr" rid="bibr4-1076029611436196">4</xref></sup>
</td>
<td>M, 77</td>
<td>3</td>
<td>nr</td>
<td>nr</td>
<td>47</td>
<td>Probably Comp Het (Ala294Val + unknown defect)</td>
<td>nr</td>
<td>No</td>
<td>Old age</td>
<td>None</td>
<td>Multicentric Study</td>
</tr>
<tr>
<td>Barnett et al<sup><xref ref-type="bibr" rid="bibr13-1076029611436196">13</xref></sup>
</td>
<td>M, 58</td>
<td>9</td>
<td>nr</td>
<td>nr</td>
<td>nr</td>
<td>Hom/nr</td>
<td>Severe (bilateral)</td>
<td>No</td>
<td>Surgery (total hip replacement); whole blood transfusion</td>
<td>None</td>
<td>PE occurred in spite of Coumadin prophylaxis</td>
</tr>
<tr>
<td>Mariani et al<sup><xref ref-type="bibr" rid="bibr20-1076029611436196">20</xref></sup>
</td>
<td>nr</td>
<td>nr</td>
<td>nr</td>
<td>nr</td>
<td>nr</td>
<td>Probably Hom/nr</td>
<td>nr</td>
<td>nr</td>
<td>aFVII concentrates</td>
<td>nr</td>
<td>Case reported as an AE to manufacturer (ref. 20)</td>
</tr>
<tr>
<td colspan="12">Marty et al<sup><xref ref-type="bibr" rid="bibr7-1076029611436196">7</xref></sup>
</td>
</tr>
<tr>
<td> Case 1</td>
<td>F, 50</td>
<td>nr</td>
<td>10</td>
<td>nr</td>
<td>86</td>
<td>Hom/Arg304Gln</td>
<td>nr</td>
<td>Yes</td>
<td>None</td>
<td>Moderate</td>
<td>
</td>
</tr>
<tr>
<td> Case 2</td>
<td>F, 79</td>
<td>nr</td>
<td>9</td>
<td>nr</td>
<td>73</td>
<td>Comp Het/Cys135Arg + Arg304Gln</td>
<td>nr</td>
<td>Yes</td>
<td>Old age</td>
<td>Mild</td>
<td>
</td>
</tr>
<tr>
<td>Arellano-Rodrigo et al<sup><xref ref-type="bibr" rid="bibr12-1076029611436196">12</xref></sup>
</td>
<td>M, 74</td>
<td>15</td>
<td>nr</td>
<td>nr</td>
<td>nr</td>
<td>Hom/nr</td>
<td>Moderate</td>
<td>Yes</td>
<td>Old age</td>
<td>None</td>
<td>LMWH</td>
</tr>
<tr>
<td>Girolami et al<sup><xref ref-type="bibr" rid="bibr8-1076029611436196">8</xref>,<xref ref-type="bibr" rid="bibr11-1076029611436196">11</xref></sup>
</td>
<td>F, 70</td>
<td>7</td>
<td>31</td>
<td>100</td>
<td>105</td>
<td>Hom/Arg304Gln</td>
<td>Moderate (bilateral)</td>
<td>No</td>
<td>Old age; hysterectomy; aFVII concentrates</td>
<td>Mild</td>
<td>Treated with UH, Coumadin</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-1076029611436196">
<p>Abbreviations: Hom, homoxygote; Comp Het, compound heterozygote; PCC, prothrombin complex concentrate; MI, myocardial infarction; UH, unfractioned heparin; LMWH, low-molecular-weight heparin; nr, not reported; AE, adverse event.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>The FVII antigen was evaluated only in 6 patients, and it varied between 20% and 105% of normal (mean 75%). Concomitant deep vein thrombosis (DVT) was present in 7 cases. Associated prothrombotic risk factors were present in 10 patients (old age in 4; surgery in 5; substitution therapy with whole blood, PCC, or activated FVII (aFVII) concentrates in 6; myocardial infarction or liver cirrhosis were present in 2 additional cases. Some patients had more than 1 prothrombotic risk factors. The role of associated congenital prothrombotic conditions could not be evaluated since a screening in this sense was carried out only in a few patients.<sup><xref ref-type="bibr" rid="bibr11-1076029611436196">11</xref>,<xref ref-type="bibr" rid="bibr12-1076029611436196">12</xref></sup> There were 2 fatalities with diagnosis confirmed at autopsy. Bleeding tendency was absent in 6 patients, whereas it was mild in 4 and moderate in 2. In 2 instances, the bleeding status was not specified.</p>
<p>Patients were homozygotes or probably homozygous in 12 cases, whereas 2 patients were compound heterozygotes. No heterozygote was found. Molecular biology studies were reported in only 4 instances. Two patients had a homozygous Arg304Gln mutation (FVII Padua), whereas the other 2 patients were compound heterozygotes (Ala294Val + unknown defect and Cys135Arg + Arg304Gln). Altogether, the Arg304Gln mutation was present in 5 of the 8 alleles. Treatment was carried out in 5 patients and consisted of low-molecular-weight heparin or unfractioned heparin plus coumarin together with substitution therapy.</p>
</sec>
<sec id="section4-1076029611436196">
<title>Discussion</title>
<p>The FVII deficiency is not known to be protective from venous thrombosis.<sup><xref ref-type="bibr" rid="bibr4-1076029611436196">4</xref>,<xref ref-type="bibr" rid="bibr6-1076029611436196">6</xref>,<xref ref-type="bibr" rid="bibr7-1076029611436196">7</xref></sup> The fact that in some patients, PE occurred without clinical evidence of DVT or other venous thrombosis indicates that the defect does not protect from PE.</p>
<p>Most of the cases presented with associated risk factors, mainly surgery, bed immobilization, and substitution therapy, with PCCs. In 2 patients, embolism was associated with aFVII concentrates (<xref ref-type="table" rid="table1-1076029611436196">Table 1</xref>). Surgery-related cases were more frequent than for DVT. This observation indicates the need for prudent use of substitution therapy in bed-confined patients. Both PCC and aFVII preparations are implicated. The thrombogenic potential of some of these preparations even in normal individuals is well known..<sup><xref ref-type="bibr" rid="bibr21-1076029611436196">21</xref>,<xref ref-type="bibr" rid="bibr22-1076029611436196">22</xref></sup> This concerns more PPC and aFVII than plasma-derived concentrates. However, the limited use of the latter may be a bias. It is interesting to note that in a few patients, PE occurred even after whole blood substitution therapy given for surgical procedures.<sup><xref ref-type="bibr" rid="bibr15-1076029611436196">15</xref>,<xref ref-type="bibr" rid="bibr17-1076029611436196">17</xref></sup> This occurrence has never been reported for DVT and this remains unexplained. An increased blood viscosity due to the administration of erythrocytes could have played a role.<sup><xref ref-type="bibr" rid="bibr17-1076029611436196">17</xref></sup>
</p>
<p>The thrombogenicity of recombinant aFVIII concentrate has received great attention in recent years. Thrombotic events occurred mainly in off-label use.<sup><xref ref-type="bibr" rid="bibr23-1076029611436196">23</xref></sup> However, several thrombotic events were reported even in hemophilia patients with inhibitors.<sup><xref ref-type="bibr" rid="bibr21-1076029611436196">21</xref></sup> As far as rare coagulation disorders are concerned, aFVII concentrates associated with thrombotic events have been reported also in hypofibrinogenemia and FXI deficiency.<sup><xref ref-type="bibr" rid="bibr24-1076029611436196">24</xref>,<xref ref-type="bibr" rid="bibr25-1076029611436196">25</xref></sup>
</p>
<p>At least 6 of these patients contained cross-reacting material (CRM) in their plasma, namely they were type 2 defects. Unfortunately, the FVII antigen status of the remaining 8 patients is unknown. Only a few type I FVII-deficient patients were reported to have manifested thrombotic events.<sup><xref ref-type="bibr" rid="bibr6-1076029611436196">6</xref></sup> This is consistent with the hypothesis that the CRM is likely to play a role.</p>
<p>Unfortunately, only a few of these cases have been studied by means of molecular biology techniques. The Arg304Gln is the most frequently encountered mutation but, due to the limited number of patients studied, no conclusions can be drawn.<sup><xref ref-type="bibr" rid="bibr8-1076029611436196">8</xref></sup>
</p>
<p>There are several considerations that can be obtained from the present study, namely (1) FVII deficiency does not protect from PE; (2) PE in these patients evolves as in normal individuals; (3) once thrombosis is diagnosed, these patients should be treated as normal patients, taking into account the basal prolongation of prothrombin time and provided the defect is corrected by the use of adequate amounts of FVII concentrates. As a consequence, patients receiving FVII concentrates for therapy during surgical procedures or even for prophylaxis should be carefully monitored for the presence of signs and symptoms of PE.</p>
<p>Finally, it is now clear that some type II defects, for example the Arg304Gln (FVII Padua) mutation, show only a mild bleeding tendency or are asymptomatic even during surgical procedures.<sup><xref ref-type="bibr" rid="bibr26-1076029611436196">26</xref>,<xref ref-type="bibr" rid="bibr27-1076029611436196">27</xref></sup> Therefore, these patients usually need little substitution therapy, if any. Among the 5 patients who were studied by molecular biology techniques, 2 were patients with homozygous Arg304Gln mutation (FVII Padua). This observation once again underscores the importance of a complete characterization of the clotting defect before submitting the patients to invasive and surgical procedures. A simple diagnosis of FVII deficiency may not be sufficient.<sup><xref ref-type="bibr" rid="bibr26-1076029611436196">26</xref>,<xref ref-type="bibr" rid="bibr28-1076029611436196">28</xref>,<xref ref-type="bibr" rid="bibr29-1076029611436196">29</xref></sup> The defect has to be characterized using at least 3 thromboplastins, namely rabbit brain, human placenta or human recombinant, and ox brain.<sup><xref ref-type="bibr" rid="bibr30-1076029611436196">30</xref><xref ref-type="bibr" rid="bibr31-1076029611436196"/>–<xref ref-type="bibr" rid="bibr32-1076029611436196">32</xref></sup> A normal result using ox brain thromboplastin is typical of the frequently encountered Arg304Gln (FVII Padua) mutation and of the rare Arg304Trp (FVII Nagoya).<sup><xref ref-type="bibr" rid="bibr33-1076029611436196">33</xref></sup> A normal FVII level obtained with ox brain thromboplastin suggests the presence of normal CRM.<sup><xref ref-type="bibr" rid="bibr6-1076029611436196">6</xref>,<xref ref-type="bibr" rid="bibr26-1076029611436196">26</xref></sup>
</p>
<p>Patients with these mutations are paucisymptomatic or asymptomatic. It is worth underscoring the sharp difference in the low protection from thrombosis exercised by FVII deficiency with the absolute one manifested by FII and/or FX deficiency.<sup><xref ref-type="bibr" rid="bibr34-1076029611436196">34</xref></sup>
</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="conflict" id="fn1-1076029611436196">
<label>Declaration of Conflicting Interests</label>
<p>The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p>
</fn>
<fn fn-type="financial-disclosure" id="fn2-1076029611436196">
<label>Funding</label>
<p>The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: supported in part by the “Associazione Emofilia ed Altre Coagulopatie delle Tre Venezie”.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1076029611436196">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Girolami</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Ruzzon</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Fabris</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Varvarikis</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Sartori</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Girolami</surname>
<given-names>B</given-names>
</name>
</person-group>. <article-title>Myocardial infarction and other arterial occlusions in hemophilia a patients. A cardiological evaluation of all 42 cases reported in the literature</article-title>. <source>Acta Haematol</source>. <year>2006</year>;<volume>116</volume>(<issue>2</issue>):<fpage>120</fpage>–<lpage>125</lpage>.</citation>
</ref>
<ref id="bibr2-1076029611436196">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Franchini</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>Thrombotic complications in patients with hereditary bleeding disorders</article-title>. <source>Thromb Haemost</source>. <year>2004</year>;<volume>92</volume>(<issue>2</issue>):<fpage>298</fpage>–<lpage>304</lpage>.</citation>
</ref>
<ref id="bibr3-1076029611436196">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Girolami</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Tezza</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Scapin</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Vettore</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Casonato</surname>
<given-names>A</given-names>
</name>
</person-group>. <article-title>Arterial and venous thrombosis in patients with von Willebrand's disease: a critical review of the literature</article-title>. <source>J Thromb Thrombolysis</source>. <year>2006</year>;<volume>21</volume>(<issue>2</issue>):<fpage>175</fpage>–<lpage>178</lpage>.</citation>
</ref>
<ref id="bibr4-1076029611436196">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mariani</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Herrmann</surname>
<given-names>FH</given-names>
</name>
<name>
<surname>Schulman</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group>
<collab collab-type="author">International Factor VII Deficiency Study Group</collab>.. <article-title>Thrombosis in inherited factor VII deficiency</article-title>. <source>J Thromb Haemost</source>. <year>2003</year>;<volume>1</volume>(<issue>10</issue>):<fpage>2153</fpage>–<lpage>2158</lpage>.</citation>
</ref>
<ref id="bibr5-1076029611436196">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Girolami</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Ruzzon</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Tezza</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Scandellari</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Vettore</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Girolami</surname>
<given-names>B</given-names>
</name>
</person-group>. <article-title>Arterial and venous thrombosis in rare congenital bleeding disorders: a critical review</article-title>. <source>Haemophilia</source>. <year>2006</year>;<volume>12</volume>(<issue>4</issue>):<fpage>345</fpage>–<lpage>351</lpage>.</citation>
</ref>
<ref id="bibr6-1076029611436196">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Girolami</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Tezza</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Scandellari</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Vettore</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Girolami</surname>
<given-names>B</given-names>
</name>
</person-group>. <article-title>Associated prothrombotic conditions are probably responsible for the occurrence of thrombosis in almost all patients with congenital FVII deficiency. Critical review of the literature</article-title>. <source>J Thromb Thrombolysis</source>. <year>2010</year>;<volume>30</volume>(<issue>2</issue>):<fpage>172</fpage>–<lpage>178</lpage>.</citation>
</ref>
<ref id="bibr7-1076029611436196">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marty</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Barro</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Chatelain</surname>
<given-names>B</given-names>
</name>
<etal/>
</person-group>. <article-title>The paradoxical association between inherited factor VII deficiency and venous thrombosis</article-title>. <source>Haemophilia</source>. <year>2008</year>;<volume>14</volume>(<issue>3</issue>):<fpage>564</fpage>–<lpage>570</lpage>.</citation>
</ref>
<ref id="bibr8-1076029611436196">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Girolami</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Candeo</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Bonamigo</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Fabris</surname>
<given-names>F</given-names>
</name>
</person-group>. <article-title>Arg 304 Gln (FVII Padua) and Ala 294 Val mutations are equally present in patients with FVII deficiency and thrombosis</article-title>. <source>Eur J Haematol</source>. <year>2011</year>;<volume>87</volume>(<issue>1</issue>):<fpage>92</fpage>–<lpage>94</lpage>.<comment>doi: 10.1111/j.1600-0609.2011.01621.x</comment>
</citation>
</ref>
<ref id="bibr9-1076029611436196">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Girolami</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Brunetti</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Cella</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Bareggi</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Virgolini</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Cafiero</surname>
<given-names>F</given-names>
</name>
</person-group>. <article-title>La ipoproconvertinemia</article-title>. <source>Biol Lat</source>. <year>1972</year>;<volume>23</volume>(<issue>4</issue>):<fpage>391</fpage>–<lpage>434</lpage>.</citation>
</ref>
<ref id="bibr10-1076029611436196">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sabharwal</surname>
<given-names>AK</given-names>
</name>
<name>
<surname>Kuppuswamy</surname>
<given-names>MN</given-names>
</name>
<name>
<surname>Foster</surname>
<given-names>DC</given-names>
</name>
<etal/>
</person-group>. <article-title>Factor VII deficiency (Factor VII Richmond, R304Q Mutant) associated with thrombosis</article-title>. <source>Circulation</source>. <year>1992</year>;<volume>86</volume>:<fpage>679</fpage>.</citation>
</ref>
<ref id="bibr11-1076029611436196">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Girolami</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Bertozzi</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Rigoni</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Muzzolon</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Vettore</surname>
<given-names>S</given-names>
</name>
</person-group>. <article-title>Bilateral pulmonary embolism in a patient with FVII Padua (Arg304Gln) after activated FVII concentrate substitution therapy for hysterectomy</article-title>. <source>J Thromb Thrombol</source>. <year>2011</year>;<volume>32</volume>(<issue>3</issue>):<fpage>362</fpage>–<lpage>367</lpage>.</citation>
</ref>
<ref id="bibr12-1076029611436196">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Arellano-Rodrigo</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Gironella</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Nicolau</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Vila</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>Clinical management of thrombosis in inherited factor VII deficiency: a description of two cases</article-title>. <source>Thromb Haemost</source>. <year>2009</year>;<volume>101</volume>(<issue>2</issue>):<fpage>402</fpage>–<lpage>404</lpage>.</citation>
</ref>
<ref id="bibr13-1076029611436196">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Barnett</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Demel</surname>
<given-names>KC</given-names>
</name>
<name>
<surname>Mega</surname>
<given-names>AE</given-names>
</name>
<name>
<surname>Butera</surname>
<given-names>JN</given-names>
</name>
<name>
<surname>Sweeney</surname>
<given-names>JD</given-names>
</name>
</person-group>. <article-title>Lack of bleeding in patients with severe factor VII deficiency</article-title>. <source>Am J Hematol</source>. <year>2005</year>;<volume>78</volume>(<issue>2</issue>):<fpage>134</fpage>–<lpage>137</lpage>.</citation>
</ref>
<ref id="bibr14-1076029611436196">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gershwin</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Gude</surname>
<given-names>JK</given-names>
</name>
</person-group>. <article-title>Deep vein thrombosis and pulmonary embolism in congenital factor VII deficiency</article-title>. <source>N Engl J Med</source>. <year>1973</year>;<volume>288</volume>(<issue>3</issue>):<fpage>141</fpage>–<lpage>142</lpage>.</citation>
</ref>
<ref id="bibr15-1076029611436196">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Godal</surname>
<given-names>HC</given-names>
</name>
<name>
<surname>Madsen</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Meyer</surname>
<given-names>RN</given-names>
</name>
</person-group>. <article-title>Thrombo-embolism in patients with total proconvertin (factor VII) deficiency. A report on two cases</article-title>. <source>Acta Med Scand</source>. <year>1962</year>;<volume>171</volume>(<issue>3</issue>):<fpage>325</fpage>–<lpage>327</lpage>.</citation>
</ref>
<ref id="bibr16-1076029611436196">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hall</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Rapaport</surname>
<given-names>SI</given-names>
</name>
<name>
<surname>Ames</surname>
<given-names>SB</given-names>
</name>
<name>
<surname>DeGroot</surname>
<given-names>JA</given-names>
</name>
</person-group>. <article-title>A clinical and family study of hereditary proconvertin (Factor VII) deficiency</article-title>. <source>Am J Med</source>. <year>1964</year>;<volume>37</volume>(<issue>8</issue>):<fpage>172</fpage>–<lpage>181</lpage>.</citation>
</ref>
<ref id="bibr17-1076029611436196">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Heikinheimo</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Reinikainen</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>Congenital factor VII deficiency. Two cases in children of cousins</article-title>. <source>Thromb Diath Haemorrh</source>. <year>1969</year>;<volume>21</volume>(<issue>2</issue>):<fpage>245</fpage>–<lpage>248</lpage>.</citation>
</ref>
<ref id="bibr18-1076029611436196">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shifter</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Machtey</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Creter</surname>
<given-names>D</given-names>
</name>
</person-group>. <article-title>Thromboembolism in congenital factor VII deficiency</article-title>. <source>Acta Haematol</source>. <year>1984</year>;<volume>71</volume>(<issue>1</issue>):<fpage>60</fpage>–<lpage>62</lpage>.</citation>
</ref>
<ref id="bibr19-1076029611436196">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Solanki</surname>
<given-names>DL</given-names>
</name>
<name>
<surname>Corn</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>Thromboembolism in patients with hereditary deficiency of coagulation factors</article-title>. <source>South Med J</source>. <year>1980</year>;<volume>73</volume>(<issue>7</issue>):<fpage>944</fpage>–<lpage>946</lpage>.</citation>
</ref>
<ref id="bibr20-1076029611436196">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mariani</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Konkle</surname>
<given-names>BA</given-names>
</name>
<name>
<surname>Ingerslev</surname>
<given-names>J</given-names>
</name>
</person-group>. <article-title>Congenital factor VII deficiency: therapy with recombinant activated factor VII—a critical appraisal</article-title>. <source>Haemophilia</source>. <year>2006</year>;<volume>12</volume>(<issue>1</issue>):<fpage>19</fpage>–<lpage>27</lpage>.</citation>
</ref>
<ref id="bibr21-1076029611436196">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>O'Connell</surname>
<given-names>KA</given-names>
</name>
<name>
<surname>Wood</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Wise</surname>
<given-names>RP</given-names>
</name>
<name>
<surname>Lozier</surname>
<given-names>JN</given-names>
</name>
<name>
<surname>Braun</surname>
<given-names>MM</given-names>
</name>
</person-group>. <article-title>Thromboembolic adverse events after use of recombinant human coagulation factor VIIa</article-title>. <source>JAMA</source>. <year>2006</year>;<volume>295</volume>(<issue>3</issue>):<fpage>293</fpage>–<lpage>298</lpage>.</citation>
</ref>
<ref id="bibr22-1076029611436196">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Witmer</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>YS</given-names>
</name>
<name>
<surname>Lynch</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Raffini</surname>
<given-names>LJ</given-names>
</name>
<name>
<surname>Shah</surname>
<given-names>SS</given-names>
</name>
</person-group>. <article-title>Off-label recombinant factor VIIa use and thrombosis in children: a multi-center cohort study</article-title>. <source>J Pediatr</source>. <year>2011</year>;<volume>158</volume>(<issue>5</issue>):<fpage>820</fpage>–<lpage>825</lpage>.</citation>
</ref>
<ref id="bibr23-1076029611436196">
<label>23</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Logan</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Yank</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Stafford</surname>
<given-names>RS</given-names>
</name>
</person-group>. <article-title>Off-label use of recombinant factor VIIa in U.S. hospitals: analysis of hospital records</article-title>. <source>Ann Int Med</source>. <year>2011</year>;<volume>154</volume>(<issue>8</issue>):<fpage>516</fpage>–<lpage>522</lpage>.</citation>
</ref>
<ref id="bibr24-1076029611436196">
<label>24</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Patiroflu</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Karakukcu</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>Middle cerebral arterial thrombosis in a patient with hypofibrinogenemia, 5 days after rFVIIa and FFP infusion</article-title>. <source>Clin Appl Thromb Hemost</source>. <year>2006</year>;<volume>12</volume>(<issue>1</issue>):<fpage>111</fpage>–<lpage>113</lpage>.</citation>
</ref>
<ref id="bibr25-1076029611436196">
<label>25</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>O’Connell</surname>
<given-names>NM</given-names>
</name>
<name>
<surname>Ridotell</surname>
<given-names>AF</given-names>
</name>
<name>
<surname>Pascoe</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Perry</surname>
<given-names>DI</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>CA</given-names>
</name>
</person-group>. <article-title>Recombinant factor VIIa to prevent surgical bleeding in factor XI deficiency</article-title>. <source>Hemophilia</source>. <year>2008</year>;<volume>14</volume>(<issue>4</issue>):<fpage>775</fpage>–<lpage>781</lpage>.</citation>
</ref>
<ref id="bibr26-1076029611436196">
<label>26</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Girolami</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Fabris</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Dal</surname>
<given-names>Bo</given-names>
</name>
<name>
<surname>Zanon</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Ghiotto</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Burul</surname>
<given-names>A</given-names>
</name>
</person-group>. <article-title>Factor VII Padua: a congenital coagulation disorder due to an abnormal factor VII with a peculiar activation pattern</article-title>. <source>J Lab Clin Med</source>. <year>1978</year>;<volume>91</volume>(<issue>3</issue>):<fpage>387</fpage>–<lpage>395</lpage>.</citation>
</ref>
<ref id="bibr27-1076029611436196">
<label>27</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kirkel</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>TW</given-names>
</name>
<name>
<surname>Fu</surname>
<given-names>SW</given-names>
</name>
<etal/>
</person-group>. <article-title>Asymptomatic factor VII deficiency: gene analysis and structure-function relationships</article-title>. <source>Blood Coagul Fibrinolysis</source>. <year>2010</year>;<volume>21</volume>(<issue>1</issue>):<fpage>91</fpage>–<lpage>94</lpage>.</citation>
</ref>
<ref id="bibr28-1076029611436196">
<label>28</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Perry</surname>
<given-names>DJ</given-names>
</name>
</person-group>. <article-title>Factor VII deficiency</article-title>. <source>Br J Haematol</source>. <year>2002</year>;<volume>118</volume>(<issue>3</issue>):<fpage>689</fpage>–<lpage>700</lpage>.</citation>
</ref>
<ref id="bibr29-1076029611436196">
<label>29</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Herrmann</surname>
<given-names>FH</given-names>
</name>
<name>
<surname>Wulff</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Auerswald</surname>
<given-names>G</given-names>
</name>
<etal/>
</person-group>
<collab collab-type="author">Greifswald Factor FVII Deficiency Study Group</collab>.. <article-title>Factor VII deficiency: clinical manifestation of 717 subjects from Europe and Latin America with mutations in the factor 7 gene</article-title>. <source>Haemophilia</source>. <year>2009</year>;<volume>15</volume>(<issue>1</issue>):<fpage>267</fpage>–<lpage>280</lpage>.</citation>
</ref>
<ref id="bibr30-1076029611436196">
<label>30</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Triplett</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Brandt</surname>
<given-names>JT</given-names>
</name>
<name>
<surname>Batard</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Dixon</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Fair</surname>
<given-names>DS</given-names>
</name>
</person-group>. <article-title>Hereditary factor VII deficiency: heterogeneity defined by combined functional and immunochemical analysis</article-title>. <source>Blood</source>. <year>1985</year>;<volume>66</volume>(<issue>6</issue>):<fpage>1284</fpage>–<lpage>1287</lpage>.</citation>
</ref>
<ref id="bibr31-1076029611436196">
<label>31</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>James</surname>
<given-names>HL</given-names>
</name>
<name>
<surname>Girolami</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Hubbard</surname>
<given-names>JG</given-names>
</name>
<name>
<surname>Kumar</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Fair</surname>
<given-names>DS</given-names>
</name>
</person-group>. <article-title>The dysfunction of coagulation factor VIIPadua results from substitution of arginine-304 by glutamine</article-title>. <source>Biochim Biophys Acta</source>. <year>1993</year>;<volume>1172</volume>(<issue>3</issue>):<fpage>301</fpage>–<lpage>305</lpage>.</citation>
</ref>
<ref id="bibr32-1076029611436196">
<label>32</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Girolami</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Bonamigo</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Vettore</surname>
<given-names>S</given-names>
</name>
</person-group>. <article-title>The lack of ties between north-eastern Italy and African-Americans suggest a multi-founder effect for FVII Padua (Arg304Gln) disorder</article-title>. <source>Blood Coagul Fibrinolysis</source>. <year>2010</year>;<volume>21</volume>(<issue>8</issue>):<fpage>775</fpage>–<lpage>776</lpage>.</citation>
</ref>
<ref id="bibr33-1076029611436196">
<label>33</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Matsushita</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Kojima</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Emi</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Takahashi</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Saito</surname>
<given-names>H</given-names>
</name>
</person-group>. <article-title>Impaired human tissue factor-mediated activity in blood clotting factor VII Nagoya (Arg304--&gt;Trp). Evidence that a region in the catalytic domain of factor VII is important for the association with tissue factor</article-title>. <source>J Biol Chem</source>. <year>1994</year>;<volume>269</volume>(<issue>10</issue>):<fpage>7355</fpage>–<lpage>7363</lpage>.</citation>
</ref>
<ref id="bibr34-1076029611436196">
<label>34</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Girolami</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Candeo</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Vettore</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Lombardi</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Girolami</surname>
<given-names>B</given-names>
</name>
</person-group>. <article-title>The clinical significance of the lack of arterial or venous thrombosis in patients with congenital prothrombin or FX deficiency</article-title>. <source>J Thromb Thrombolysis</source>. <year>2010</year>;<volume>29</volume>(<issue>3</issue>):<fpage>299</fpage>–<lpage>302</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>